Best-selling in Health, Treatments & Medicine
Save on Health, Treatments & Medicine
- £30.58Trending at £34.04
- £6.95Trending at £10.28
- £14.33Trending at £17.52
- £25.99Trending at £30.39
- £24.06Trending at £27.07
- £29.31Trending at £31.56
- £22.50Trending at £29.20
About this product
- PublisherElsevier Science Publishing Co Inc
- Date of Publication03/09/2015
- GenreClinical Medicine: Professional
- Country of PublicationUnited States
- ImprintElsevier Science Publishing Co Inc
- Weight880 g
- Width191 mm
- Height235 mm
- Edited byAmitava DasGupta,Michael Oellerich
- Table Of ContentsChapter 1. Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring Chapter 2. Limitations of Immunoassays Used for Therapeutic Drug Monitoring of Immunosuppressants Chapter 3. Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants Chapter 4. Monitoring Free Mycophenolic Acid Concentration: Is There any Clinical Advantage? Chapter 5. Pharmacogenomics aspect of immunosuppressant therapy Chapter 6. Biomarker monitoring in immunosuppressant therapy: An overview Chapter 7. Graft-derived cell-free DNA as a Marker of Graft Integrity after Transplantation Chapter 8. Biomarkers of tolerance in kidney transplantation Chapter 9. Intracellular concentrations of immunosuppressants Chapter 10. Markers of lymphocyte activation and proliferation Chapter 11. Monitoring Calcineurin inhibitors response based on NFAT-regulated gene expression
- Author BiographyMichael Oellerich, MD, HonMD, FACB, FAMM, FFPath (RCPI), FRCPath, is a chemical pathologist. Since 2012, he has had an appointment as a Lower Saxony Distinguished Professor of Clinical Chemistry at the Department of Clinical Pharmacology, Medical Faculty (UMG) of the George-August University, Gottingen, Germany. He was Chairman of the Department of Clinical Chemistry/Central Laboratory at UMG from 1991 to 2012. Since 2013, he has been a member of the Medical Advisory Board of Chronix Biomedical Inc., San Jose, CA, USA. From 1996 to 1998, he served as Dean of the Faculty of Medicine. He also served as President of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), the German Association for Laboratory Medicine, the German United Association for Clinical Chemistry and Laboratory Medicine, and the World Association of Societies of Pathology and Laboratory (WASPaLM). Since 2003, he has been Editor-in-Chief of Therapeutic Drug Monitoring. Previously, he was Associate Editor of Clinical Biochemistry and of Clinical Chemistry. His current research interests are in the field of therapeutic drug monitoring, with particular focus on endogenous biomarkers to achieve personalized immunosuppression in transplantation (e.g. graft-derived circulating cell-free DNA as liquid biopsy ), as well as pharmacogenetics. Further topics include proteomics, analytical techniques (e.g. LC-MS/MS), and molecular diagnostics. He has authored more than 400 publications, and has received various awards (e.g. Ludolf-Krehl Award, IATDMCT Charles Pippenger Award, WASPaLM Medal of Honor, WASPaLM Gold-Headed Cane). Amitava Dasgupta received his PhD degree in Chemistry from Stanford University and his fellowship training in Clinical Chemistry from the Laboratory Medicine Department of the University of Washington School of Medicine at Seattle. He is a tenured Full Professor of Pathology and Laboratory Medicine at the University of Texas Health Sciences Center located at the Texas Medical Center at Houston. Dr. Dasgupta has published 210 scientific papers, written many invited review articles, and has edited, co-edited or written 15 books. He is on the Editorial Board of five major medical journals including American Journal of Clinical Pathology, Archives of Pathology and Laboratory Medicine, Therapeutic Drug Monitoring, Clinica Chimica Acta and Journal of Clinical Laboratory Analysis.
This item doesn't belong on this page.
Thanks, we'll look into this.